Abstract
The Summary of Product Characteristics (SmPC) is an obligatory document concerning a medicine required (among other things) for the authorization of a medicinal product. The purpose of the SmPC is to provide product information to healthcare professionals. A necessary condition for this is to ensure that the SmPC is clear and precise. However, neither European nor national legislation obliges marketing authorization holders to review the SmPC in terms of its readability and understandability prior to the registration of a medicine. To date, research on SmPCs has focused on accuracy and completeness; however, the literature lacks information on the extent to which SmPCs meet the needs of healthcare professionals concerning the readability of the information they contain. The main objective of this article is to point out the lack of precision in the legal provisions for the preparation of SmPCs concerning the comprehensibility of the provisions. The article points to the lack of testing of the SmPC in terms of accessibility and transparency for healthcare professionals, highlighting that the document does not meet the needs of healthcare professionals in providing adequate information about medicines. It shows that the current rules and guidelines for the preparation of the registration dossier for a medicinal product are not entirely precise and contain numerous shortcomings.
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health
Reference20 articles.
1. EudraLex—Volume 2—Pharmaceutical Legislation on Notice to Applicants and Regulatory Guidelines for Medicinal Products for Human Usehttp://ec.europa.eu/health/documents/eudralex/vol
2. DIRECTIVE 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Usehttp://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20091005:PL:PDF
3. A Guideline on Summary of Product Characteristics (SmPC)http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf.
4. Physicians prefer greater detail in the biosimilar label (SmPC) – Results of a survey across seven European countries
5. How to keep good clinical records
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献